![Pharmaceutical compositions comprising 4-(6Br,10aS)-3-methyl-2, 3, 6b, 9, 10, 10a-hexahydro-1H, 7H-pyrido[3′, 4′, 5] pyrolo[1,2,3-de] quinoxalin-8YL)-1-(4-fluorophenyl)-butane-1-one and methods of treating conditions of the central nervous system](/docs/US/2023-06-20/US11680065B2/abs.jpg.600x600.jpg)
- Patent Title: Pharmaceutical compositions comprising 4-(6Br,10aS)-3-methyl-2, 3, 6b, 9, 10, 10a-hexahydro-1H, 7H-pyrido[3′, 4′, 5] pyrolo[1,2,3-de] quinoxalin-8YL)-1-(4-fluorophenyl)-butane-1-one and methods of treating conditions of the central nervous system
-
Application No.: US17072933Application Date: 2020-10-16
-
Publication No.: US11680065B2Publication Date: 2023-06-20
- Inventor: Peng Li , Qiang Zhang , Robert Davis , Lawrence P. Wennogle
- Applicant: INTRA-CELLULAR THERAPIES, INC.
- Applicant Address: US NY New York
- Assignee: INTRA-CELLULAR THERAPIES, INC.
- Current Assignee: INTRA-CELLULAR THERAPIES, INC.
- Current Assignee Address: US NY New York
- Agency: Hoxie & Associates LLC
- The original application number of the division: US16591178 2019.10.02
- Main IPC: A61K31/437
- IPC: A61K31/437 ; C07D471/22 ; C07D471/16 ; C07D471/14 ; A61K9/50 ; A61K9/48 ; A61K31/4985 ; A61K47/34 ; A61K47/38
![Pharmaceutical compositions comprising 4-(6Br,10aS)-3-methyl-2, 3, 6b, 9, 10, 10a-hexahydro-1H, 7H-pyrido[3′, 4′, 5] pyrolo[1,2,3-de] quinoxalin-8YL)-1-(4-fluorophenyl)-butane-1-one and methods of treating conditions of the central nervous system](/abs-image/US/2023/06/20/US11680065B2/abs.jpg.150x150.jpg)
Abstract:
The invention relates to pharmaceutical compositions comprising, compounds of Formula Q:
wherein W is —N(H)—, or —N(CH3)—, and Y is —C(═O)— or —O—, in free base or pharmaceutically acceptable salt form, and methods of use in the treatment of diseases involving 5-HT2A receptor, serotonin transporter (SERT) pathway and/or the dopamine D2 receptor pathway, and methods of treating conditions of the central nervous system therewith.
wherein W is —N(H)—, or —N(CH3)—, and Y is —C(═O)— or —O—, in free base or pharmaceutically acceptable salt form, and methods of use in the treatment of diseases involving 5-HT2A receptor, serotonin transporter (SERT) pathway and/or the dopamine D2 receptor pathway, and methods of treating conditions of the central nervous system therewith.
Public/Granted literature
Information query
IPC分类:
